BDTX vs RVMD
BDTX: Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across multiple cancer types, with a focus on brain-penetrant therapies for lung cancer and glioblastoma. RVMD: A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital.
Side-by-side fundamentals
| Metric | BDTX | RVMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.83 | $183.03 | |
| Market cap as of 2026-07-23 | $106M | $39.0B | |
| P/E as of 2026-07-23 | 4.74 | n/a | |
| PEG as of 2026-07-23 | n/a | -0.34 | |
| Net margin as of 2026-07-23 | +31.9% | -2833.9% | BDTX higher |
| Operating margin as of 2026-07-23 | +17.9% | -3145.0% | BDTX higher |
| ROE as of 2026-07-23 | -36.4% | -54.1% | BDTX higher |
| ROA as of 2026-07-23 | -28.8% | -39.1% | BDTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.19 | BDTX lower |
| Beta as of 2026-07-23 | 3.23 | 1.41 | |
| 1-year return as of 2026-07-22 close | -40.6% | +378.3% | RVMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.